Olezarsen, formerly known as IONIS-APOCIII-LRx and AKCEA-APOCIII-LRx, is an RNA-targeted investigational LIgand-Conjugated Antisense (LICA) medicine being evaluated for people at risk of disease due to elevated triglyceride levels, including those with severe hypertriglyceridemia (sHTG). Olezarsen is designed to inhibit the body’s production of apoC-III, a protein produced in the liver that regulates triglyceride metabolism in the blood.
About Severe Hypertriglyceridemia (sHTG)
sHTG is a condition in which a person’s triglyceride levels are dangerously high. Although a healthy triglyceride level for adults is typically below 150 mg/dL, people living with sHTG often have levels greater than 500 mg/dL. Triglycerides are a type of fat that the body uses as an important source of energy. However, this condition leads to the build-up of large triglyceride-containing particles called chylomicrons in the blood, which can result in severe health complications, including cardiovascular disease and potentially fatal acute pancreatitis (AP). It is estimated there are greater than three million people living with sHTG in the U.S.
Safety and efficacy have not been evaluated by any regulatory authorities for the indication described.